Evidence of determinant spreading in the antibody responses to prostate cell surface antigens in patients immunized with prostate-specific antigen

Clinical Cancer Research

Volumn 8, Issue 2, 2002, Pages 368-373

  Cavacini, Lisa A ^a,c   Duval, Mark ^a   Eder, J Paul ^b,c   Posner, Marshall R ^a,b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPITOPE; IMMUNOGLOBULIN G; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT VACCINE;

ANTIBODY RESPONSE; ARTICLE; BIRD DISEASE; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOREACTIVITY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL LINE; VACCINIA;

CANCER VACCINES; CELL MEMBRANE; EPITOPES; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0036184731     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Demonstration of a rational strategy for human prostate cancer gene therapy
2. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines
3. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
4. Phase II prostate cancer vaccine trial: Report or a study involving 37 patients with disease recurrence following primary treatment
5. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A Phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
6. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
7. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses
8. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro
9. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man
10. Immunologic approaches to the treatment of prostate cancer
11. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer
12. A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer
13. Signaling antibodies in cancer therapy
14. New insights into anti-HER-2 receptor monoclonal antibody research
15. Untangling the ErbB signalling network
16. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy
17. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function
18. Signaling events involved in anti-CD20 induced apoptosis of malignant human B cells
19. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinoma
20. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses
21. Loss of HLA class I expression in prostate cancer. Implications for immunotherapy
22. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen
23. Induction of autoimmunity by multivalent immunodominant and subdominant T cell determinants of La(SS-B)
24. Determinant spreading of T helper cell 2 (Th2) responses to pancreatic islet autoantigens
25. Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis
26. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis
27. Prostate adenocarcinoma cells release the novel proinflammatory polypeptide EMAP-II in response to stress
28. Treatment of human B cell lymphoma xenografts with a CD3×CD19 diabody and T cells
29. Requirements for the construction of antibody heterodimers for the direction of lysis of tumors by human T cells
30. Targeting of cytotoxic cells with heterocrosslinked antibodies
31. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies
32. Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy
33. Targeting of bivalent anti-erbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity
34. Intracellular antibody-caspase-mediated cell killing: An approach for application in cancer therapy